Single User License
INR 135860
Site License
INR 271720
Corporate User License
INR 407580

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Spinal Cord Injury-Pipeline Review, H2 2016

Spinal Cord Injury-Pipeline Review, H2 2016


  Request for Sample Report

Executive Summary

Spinal Cord Injury-Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinal Cord Injury-Pipeline Review, H2 2016, provides an overview of the Spinal Cord Injury (Central Nervous System) pipeline landscape.

Spinal cord injury (SCI) is defined as damage or trauma caused to the spinal cord. SCI can lead to loss or impaired function resulting in reduced mobility or feeling. It is usually caused by trauma, transverse myelitis, polio, spina bifida or Friedreich's ataxia. Signs and symptoms of spinal cord injury include extreme back pain or pressure in the neck, head or back, paralysis in any part of the body, numbness, tingling or loss of sensation in the hands, fingers, feet or toes, loss of bladder or bowel control, difficulty in walking and impaired breathing after injury.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Spinal Cord Injury-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Spinal Cord Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Spinal Cord Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Spinal Cord Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 10, 7, 23 and 6 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 15 and 2 molecules, respectively.Spinal Cord Injury.

Spinal Cord Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Spinal Cord Injury (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Spinal Cord Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Spinal Cord Injury (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Spinal Cord Injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Spinal Cord Injury (Central Nervous System)

Reasons To Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Spinal Cord Injury (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Spinal Cord Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Spinal Cord Injury Overview 8

Therapeutics Development 9

Pipeline Products for Spinal Cord Injury-Overview 9

Pipeline Products for Spinal Cord Injury-Comparative Analysis 10

Spinal Cord Injury-Therapeutics under Development by Companies 11

Spinal Cord Injury-Therapeutics under Investigation by Universities/Institutes 14

Spinal Cord Injury-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Spinal Cord Injury-Products under Development by Companies 18

Spinal Cord Injury-Products under Investigation by Universities/Institutes 21

Spinal Cord Injury-Companies Involved in Therapeutics Development 22

AbbVie Inc 22

Acorda Therapeutics Inc 23

Asterias Biotherapeutics, Inc. 24

Asubio Pharma Co Ltd 25

Athersys Inc 26

BioArctic Neuroscience AB 27

BioAxone BioSciences Inc 28

Genervon Biopharmaceuticals LLC 29

Histocell SL 30

Kadimastem Ltd 31

Kringle Pharma Inc 32

Lpath Inc 33

MandalMed Inc 34

Mapreg SAS 35

Medgenics Inc 36

Neuralstem Inc 37

Neuronax SAS 38

New World Laboratories Inc 39

Omeros Corp 40

PharmatrophiX, Inc. 41

Pharmicell Co Ltd 42

Protagenic Therapeutics Inc. 43

Q Therapeutics Inc 44

Remedy Pharmaceuticals Inc 45

RespireRx Pharmaceuticals Inc 46

SanBio Inc 47

Stemedica Cell Technologies Inc 48

TissueGene Inc 49

TRB Chemedica International SA 50

Tumorend LLC 51

Vertex Pharmaceuticals Inc 52

Vicore Pharma AB 53

Spinal Cord Injury-Therapeutics Assessment 54

Assessment by Monotherapy Products 54

Assessment by Combination Products 55

Assessment by Target 56

Assessment by Mechanism of Action 59

Assessment by Route of Administration 62

Assessment by Molecule Type 64

Drug Profiles 66

(buspirone + carbidopa + levodopa)-Drug Profile 66

ABT-555-Drug Profile 67

AP-325-Drug Profile 68

APO-1-Drug Profile 69

ASTOPC-1-Drug Profile 70

AX-007-Drug Profile 76

BA-277-Drug Profile 77

BA-434-Drug Profile 78

C-21-Drug Profile 79

Cell Therapy for Spinal Cord Injury-Drug Profile 81

Cell Therapy to Activate hNT-3 for Spinal Cord and Traumatic Brain Injury-Drug Profile 82

Cellgram-SCI-Drug Profile 83

CHEC-7-Drug Profile 84

CHEC-9-Drug Profile 85

chondroitinase ABC nanosphere-Drug Profile 86

CLR-01-Drug Profile 87

CM-101-Drug Profile 88

CX-717-Drug Profile 89

Drug for Spinal Cord Injury-Drug Profile 91

FAB-117HC-Drug Profile 92

Gene Therapy for Spinal Cord Injury and Neurodegenerative Diseases-Drug Profile 93

glyburide-Drug Profile 94

GM-603-Drug Profile 97

HBN-1-Drug Profile 98

ICCN-100-Drug Profile 99

IMS-001-Drug Profile 100

IMS-002-Drug Profile 101

JM-4-Drug Profile 102

KP-100IT-Drug Profile 103

LM11A-31BHS-Drug Profile 105

LPA-181-Drug Profile 107

Lpathomab-Drug Profile 108

MAP-4343-Drug Profile 111

Neu-2000-Drug Profile 112

NeuroRelease SCI-Drug Profile 113

neurovitas-Drug Profile 114

NOVO-117-Drug Profile 115

NSI-566-Drug Profile 116

NWL-53-Drug Profile 124

NX-210-Drug Profile 125

Oligonucleotide for Central Nervous System and Metabolic Disorders-Drug Profile 126

PF-05285401-Drug Profile 127

porcine GM1 ganglioside-Drug Profile 137

PT-00114-Drug Profile 138

Q-Cells-Drug Profile 139

Recombinant Chondroitinase to Inhibit Chondroitin Sulfate Proteoglycan for Spinal Cord Injury and Brain Injury-Drug Profile 141

Recombinant Protein to Antagonize EPHA4 for ALS, Acute Spinal Cord Injury and Ischemia Reperfusion Injury-Drug Profile 142

SB-618-Drug Profile 143

SB-623-Drug Profile 144

SC-0806-Drug Profile 148

Small Molecule to Antagonize GPR17 for Central Nervous System Disorders-Drug Profile 149

Small Molecules for Spinal Cord Injury-Drug Profile 150

Small Molecules to Block Voltage-Gated Potassium Channel for Spinal Cord Injury and Multiple Sclerosis-Drug Profile 151

Stem Cell Therapy for Central Nervous System Disorders-Drug Profile 152

Stem Cell Therapy for CNS Disorders-Drug Profile 153

Stem Cell Therapy for Neurodegenerative Diseases-Drug Profile 154

Stem Cell Therapy for Spinal Cord Injury-Drug Profile 156

Stem Cell Therapy for Spinal Cord Injury-Drug Profile 157

Stem Cell Therapy for Spinal Cord Injury-Drug Profile 158

SUN-13837-Drug Profile 159

Synthetic Peptide to Antagonize PTPRS for Spinal Cord Injury-Drug Profile 160

Synthetic Peptides to Activate SDF-1 Alpha for CNS Disorders and Infectious Disease-Drug Profile 161

TG-N-Drug Profile 162

UH-0113-Drug Profile 163

UH-0213-Drug Profile 164

VX-210-Drug Profile 165

Spinal Cord Injury-Dormant Projects 168

Spinal Cord Injury-Discontinued Products 174

Spinal Cord Injury-Product Development Milestones 175

Featured News & Press Releases 175

Appendix 186

Methodology 186

Coverage 186

Secondary Research 186

Primary Research 186

Expert Panel Validation 186

Contact Us 186

Disclaimer 187

List of Figures

Number of Products under Development for Spinal Cord Injury, H2 2016 14

Number of Products under Development for Spinal Cord Injury-Comparative Analysis, H2 2016 15

Number of Products under Development by Companies, H2 2016 16

Number of Products under Investigation by Universities/Institutes, H2 2016 19

Comparative Analysis by Clinical Stage Development, H2 2016 21

Comparative Analysis by Early Stage Products, H2 2016 22

Assessment by Monotherapy Products, H2 2016 59

Number of Products by Top 10 Targets, H2 2016 61

Number of Products by Stage and Top 10 Targets, H2 2016 61

Number of Products by Top 10 Mechanism of Actions, H2 2016 64

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 64

Number of Products by Routes of Administration, H2 2016 67

Number of Products by Stage and Routes of Administration, H2 2016 67

Number of Products by Top 10 Molecule Types, H2 2016 69

Number of Products by Stage and Top 10 Molecule Types, H2 2016 69

List of Tables

Number of Products under Development for Spinal Cord Injury, H2 2016 14

Number of Products under Development for Spinal Cord Injury-Comparative Analysis, H2 2016 15

Number of Products under Development by Companies, H2 2016 16

Number of Products under Development by Companies, H2 2016 (Contd..1) 17

Number of Products under Development by Companies, H2 2016 (Contd..2) 18

Number of Products under Investigation by Universities/Institutes, H2 2016 19

Comparative Analysis by Late Stage Development, H2 2016 20

Comparative Analysis by Clinical Stage Development, H2 2016 21

Comparative Analysis by Early Stage Development, H2 2016 22

Products under Development by Companies, H2 2016 23

Products under Development by Companies, H2 2016 (Contd..1) 24

Products under Development by Companies, H2 2016 (Contd..2) 25

Products under Investigation by Universities/Institutes, H2 2016 26

Spinal Cord Injury-Pipeline by AbbVie Inc, H2 2016 27

Spinal Cord Injury-Pipeline by Acorda Therapeutics Inc, H2 2016 28

Spinal Cord Injury-Pipeline by Asterias Biotherapeutics, Inc., H2 2016 29

Spinal Cord Injury-Pipeline by Asubio Pharma Co Ltd, H2 2016 30

Spinal Cord Injury-Pipeline by Athersys Inc, H2 2016 31

Spinal Cord Injury-Pipeline by BioArctic Neuroscience AB, H2 2016 32

Spinal Cord Injury-Pipeline by BioAxone BioSciences Inc, H2 2016 33

Spinal Cord Injury-Pipeline by Genervon Biopharmaceuticals LLC, H2 2016 34

Spinal Cord Injury-Pipeline by Histocell SL, H2 2016 35

Spinal Cord Injury-Pipeline by Kadimastem Ltd, H2 2016 36

Spinal Cord Injury-Pipeline by Kringle Pharma Inc, H2 2016 37

Spinal Cord Injury-Pipeline by Lpath Inc, H2 2016 38

Spinal Cord Injury-Pipeline by MandalMed Inc, H2 2016 39

Spinal Cord Injury-Pipeline by Mapreg SAS, H2 2016 40

Spinal Cord Injury-Pipeline by Medgenics Inc, H2 2016 41

Spinal Cord Injury-Pipeline by Neuralstem Inc, H2 2016 42

Spinal Cord Injury-Pipeline by Neuronax SAS, H2 2016 43

Spinal Cord Injury-Pipeline by New World Laboratories Inc, H2 2016 44

Spinal Cord Injury-Pipeline by Omeros Corp, H2 2016 45

Spinal Cord Injury-Pipeline by PharmatrophiX, Inc., H2 2016 46

Spinal Cord Injury-Pipeline by Pharmicell Co Ltd, H2 2016 47

Spinal Cord Injury-Pipeline by Protagenic Therapeutics Inc., H2 2016 48

Spinal Cord Injury-Pipeline by Q Therapeutics Inc, H2 2016 49

Spinal Cord Injury-Pipeline by Remedy Pharmaceuticals Inc, H2 2016 50

Spinal Cord Injury-Pipeline by RespireRx Pharmaceuticals Inc, H2 2016 51

Spinal Cord Injury-Pipeline by SanBio Inc, H2 2016 52

Spinal Cord Injury-Pipeline by Stemedica Cell Technologies Inc, H2 2016 53

Spinal Cord Injury-Pipeline by TissueGene Inc, H2 2016 54

Spinal Cord Injury-Pipeline by TRB Chemedica International SA, H2 2016 55

Spinal Cord Injury-Pipeline by Tumorend LLC, H2 2016 56

Spinal Cord Injury-Pipeline by Vertex Pharmaceuticals Inc, H2 2016 57

Spinal Cord Injury-Pipeline by Vicore Pharma AB, H2 2016 58

Assessment by Monotherapy Products, H2 2016 59

Assessment by Combination Products, H2 2016 60

Number of Products by Stage and Target, H2 2016 62

Number of Products by Stage and Mechanism of Action, H2 2016 65

Number of Products by Stage and Route of Administration, H2 2016 68

Number of Products by Stage and Molecule Type, H2 2016 70

Spinal Cord Injury-Dormant Projects, H2 2016 173

Spinal Cord Injury-Dormant Projects (Contd..1), H2 2016 174

Spinal Cord Injury-Dormant Projects (Contd..2), H2 2016 175

Spinal Cord Injury-Dormant Projects (Contd..3), H2 2016 176

Spinal Cord Injury-Dormant Projects (Contd..4), H2 2016 177

Spinal Cord Injury-Dormant Projects (Contd..5), H2 2016 178

Spinal Cord Injury-Discontinued Products, H2 2016 179

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc, Acorda Therapeutics Inc, Asterias Biotherapeutics, Inc., Asubio Pharma Co Ltd, Athersys Inc, BioArctic Neuroscience AB, BioAxone BioSciences Inc, Genervon Biopharmaceuticals LLC, Histocell SL, Kadimastem Ltd, Kringle Pharma Inc, Lpath Inc, MandalMed Inc, Mapreg SAS, Medgenics Inc, Neuralstem Inc, Neuronax SAS, New World Laboratories Inc, Omeros Corp, PharmatrophiX, Inc., Pharmicell Co Ltd, Protagenic Therapeutics Inc., Q Therapeutics Inc, Remedy Pharmaceuticals Inc, RespireRx Pharmaceuticals Inc, SanBio Inc, Stemedica Cell Technologies Inc, TissueGene Inc, TRB Chemedica International SA, Tumorend LLC, Vertex Pharmaceuticals Inc, Vicore Pharma AB

Spinal Cord Injury Therapeutic Products under Development, Key Players in Spinal Cord Injury Therapeutics, Spinal Cord Injury Pipeline Overview, Spinal Cord Injury Pipeline, Spinal Cord Injury Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com